Literature DB >> 19579295

Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.

Ajay K Singh1.   

Abstract

Some time has passed since the torrent of discussion surrounding the cardiovascular risk of pushing up hemoglobin concentrations in dialysis patients with erythropoietin. The debate here reflects a look back on the tension produced by confusing data and outcomes. Is it the target hemoglobin per se or the high doses of erythropoietin in subsets of resistant patients that is the problem? You decide.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19579295     DOI： 10.1681/asn.2009040444

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


  6 in total

1.  Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.

Authors:  S T Provatopoulou; P N Ziroyiannis
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

2.  Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19-A Single Center Experience.

Authors:  Andrei Niculae; Ileana Peride; Ana-Maria Nechita; Lucian Cristian Petcu; Mirela Tiglis; Ionel Alexandru Checherita
Journal:  J Pers Med       Date:  2022-06-13

3.  Intravenous iron in digestive diseases: a clinical (re)view.

Authors:  Fernando Gomollón; Javier P Gisbert; José Antonio García-Erce
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

4.  A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.

Authors:  Gregory Fusco; Ali Hariri; Carlos Vallarino; Ajay Singh; Peter Yu; Lesley Wise
Journal:  Ther Adv Drug Saf       Date:  2017-07-12

5.  Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).

Authors:  Haesuk Park; Xinyue Liu; Linda Henry; Jeffrey Harman; Edward A Ross
Journal:  BMC Nephrol       Date:  2018-11-09       Impact factor: 2.388

6.  First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.

Authors:  Lutz Renders; Klemens Budde; Christian Rosenberger; Rachel van Swelm; Dorine Swinkels; Frank Dellanna; Werner Feuerer; Ming Wen; Christiane Erley; Birgit Bader; Claudia Sommerer; Matthias Schaier; Karoline Meurer; Louis Matis
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.